What Shoulder Innovations (SI) Said on Its Q3 Earnings Call

Shoulder Innovations (SI) reported Q3 expenses rising due to hiring and R&D. Cash reserves were $92.3M, with improved burn rate. Surgeon growth and implant volume increased 34% YoY. New products and partnerships were announced, with FDA submissions planned for 2027. Management expects cash flow break-even with current reserves.

Original reporting
Published Nov 8, 2026, 1:14 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 8, 2026, 1:26 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
What Shoulder Innovations (SI) Said on Its Q3 Earnings Call — source image
Decision brief

The 30-second read

$SINeutralMed
01

Why it matters

The earnings release provides the first public numbers for the quarter, offering fresh data for valuation and trade decisions.

02

Market read

Micro‑cap med‑device earnings with new product milestones; relevance mainly to investors in SI and sector peers.

03

What to watch

Potential reimbursement pressure from outpatient settings and upcoming FDA submissions.

Relevance 6/10Novelty 6/10Timing: post-earnings today

Background

Shoulder Innovations (SI) reported its Q3 earnings, detailing financials, surgeon growth, and upcoming product launches.

Company-level read

Ticker impact

$SINeutralMedium confidence
Context

Shoulder Innovations disclosed Q3 financial results, cash position, expense increases, and product pipeline updates on its earnings call.

Expected impact

potential modest upside as investors weigh cash runway against higher expenses

Evidence & confidence

New guidance and product milestones provide fresh data, but expense growth tempers enthusiasm.

Market effects

Highlights continued investment in shoulder arthroplasty technology, may spur interest in med‑device peers.

U.S. med‑device sector sees mixed signals from expense growth versus cash strength.

Limited to niche orthopedic market; no broad macro impact.

Counterpoint

Higher SG&A and R&D could erode near‑term profitability, suggesting caution.

Key entities

  • Shoulder Innovations

    Medical device firm focused on shoulder arthroplasty.

Related articles

$SIMedAI 8/10

Shoulder Innovations (SI) Q3 2026 Earnings Call Transcript

Shoulder Innovations reported Q3 2026 net revenue of $16.2M, up 38% YoY, with gross margin at 78.5%. The company raised full-year revenue guidance to $68M-$70M, up 44%-48% YoY. They launched new products, including the InSet Go glenoid implant, and saw strong surgeon adoption and procedural growth. The company expects continued momentum and plans to expand its commercial team.

$SIHigh

Shoulder Innovations Reports Third Quarter 2026 Financial Results and Raises Full Year Outlook

SHOULDER INNOVATIONS, INC. (SI) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Shoulder Innovations Reports Third Quarter 2026 Financial Results and Raises Full Year Outlook 52% Year-to-Date 2026 Revenue Growth Grand Rapids, MI – November 5, 2026 – Shoulder Innovations, Inc. (Shoulder Innovations, or the company) (NYSE: SI), a commercial-stage

$SIMed

22 Humeral Head and Initiates Full Commercial Launch – Ortho Spine News

Shoulder Innovations (NYSE: SI) received FDA 510(k) clearance for its N-22 Humeral Head, a titanium implant for metal-sensitive patients. The company also launched the product commercially. The N-22 Humeral Head complements the N-22 Glenosphere, cleared earlier this year, for use in shoulder arthroplasty procedures. According to the company, this expansion may enhance surgeon relationships and operational centers. Shoulder Innovations focuses on shoulder surgical care, offering advanced implant

$SIMed

Shoulder Innovations Q2 Earnings Call Highlights

Shoulder Innovations (NYSE:SI) reported Q2 gross margin of 78.3% versus 76.2% a year earlier, with SG&A rising to $20.1M and R&D to $3.4M. Net loss narrowed to $10.2M. Cash totaled $99M at June 30. The company expects similar gross margins in 2H 2026 and plans FDA submissions for its robotic platform in 2027.